Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBIn an interview, Jaime Merchan, MD, explained the background and data from a biomarker analysis of the CLEAR trial in advanced renal cell carcinoma. Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets …
WEBAug 16, 2024 · The pivotal phase 3 inMIND trial (NCT04680052) of tafasitamab-cxix (Monjuvi), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody in combination with lenalidomide (Revlimid) and rituximab (Rituxan) vs lenalidomide and rituximab alone in patients with relapsed or refractory follicular lymphoma (FL) met its …
Navigating Treatment Options for HER2+ BC: A Need for …
WEBAug 21, 2024 · The Playback API request failed for an unknown reason. The DAPHNe trial (NCT03716180) investigated the prevalence and dynamics of circulating tumor DNA (ctDNA) in patients with early-stage HER2-positive breast cancer undergoing neoadjuvant therapy. In the study, 92% of patients had detectable ctDNA at baseline, suggesting …
A Phase II Trial of Cetuximab and Docetaxel With Radiation for …
WEBApr 20, 2017 · In this phase II study, cetuximab 400 mg/m2 was given in the usual loading dose only on day 1 of week 1 and then, subsequently, in 250 mg/m2 weekly doses on day 1 of each following week (weeks 2-7). Docetaxel 20 mg/m2 was administered weekly on day 1 from weeks 2-7. Radiotherapy consisted of 0.5 Gy/fraction twice a day at least 6 hours …
Nadofaragene Firadenovec Now Fully Available for BCG …
WEBJan 16, 2024 · The real-world evidence study titled ABLE-41 U.S. (NCT06026332) is evaluating nadofaragene firadenovec and currently enrolling patients. Nadofaragene firadenovec-vncg is now fully available for adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with CIS with or without papillary tumors across the …
TAS-102 Receives FDA Approval for Gastric/GEJ Cancer
WEBFeb 25, 2019 · Patients were randomized 2:1 to receive TAS-102 (35 mg/m 2 twice daily on days 1 to 5 and 8 to 12 of each 28-day cycle) or placebo plus best supportive care, and were treated until progression, intolerability, or patient withdrawal. The primary cancer site was gastric in 71% and GEJ in 29%. Fifty-five percent had ≥3 metastatic sites.
Continuing Osimertinib Treatment After Progression Prolongs …
WEBJan 25, 2019 · The investigators said that continuing osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clinical benefit in selected patients. They suggested that further study will be needed, especially given the increasing role for osimertinib in the treatment of EGFR -mutant advanced NSCLC. Reference:
Lenvatinib/Pembrolizumab Improves Survival in …
WEBMar 19, 2024 · The combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) led to improvements in overall survival (OS) and progression-free survival (PFS) vs chemotherapy across most patients with advanced/recurrent endometrial cancer, according to findings from the phase 3 ENGOT-en9/LEAP-001 study (NCT03884101) presented at …
Tiragolumab-Atezolizumab Combo Shows Preliminary Clinical …
WEBJul 3, 2021 · As of the data cut-off on April 8, 2021, 21 patients with metastatic esophageal cancer were treated with tiragolumab plus atezolizumab. Patients were a median age of 62 years (range, 50-77). In addition, the majority were male (86%) and White (43%). Overall, 76% had an ECOG performance score of 1, 38% of patients has 2 lines of prior …
Docetaxel Continues to Show Profound Benefits in Prostate Cancer
WEBJan 14, 2017 · In the larger STAMPEDE trial (2962 patients), adding docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naïve advanced prostate cancer. The median overall survival (OS) was 81 months with docetaxel plus standard of care (hormonal therapy with or without radiotherapy) …
Skip to content